Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007

The Pediatric Infectious Disease Journal
Katherine K HsuMassachusetts Department of Public Health

Abstract

Heptavalent pneumococcal conjugate vaccine (PCV7) was licensed in the United States in February 2000 and distributed in Massachusetts, starting in July 2000 for universal administration to children <2 years of age and selected use in children 2 to 5 years of age. Statewide surveillance was begun in October 2001 to monitor incidence of invasive disease, serotypes causing disease, antimicrobial susceptibility, and risk features associated with ongoing childhood invasive pneumococcal disease (IPD). Massachusetts pediatric IPD cases were identified via enhanced passive surveillance of microbiology laboratory reports of pneumococcal isolates from sterile body sites of children <18 years. Serotyping and antimicrobial susceptibility testing were performed on isolates of Streptococcus pneumoniae from normally sterile body fluid. Demographic and clinical data, were collected via follow-up telephone interviews with primary care providers. Incidence rates were derived using Census 2000 denominators. A total of 586 IP cases were reported between October 2001 and September 2007. Among 433 (74%) cases with isolates available for serotyping, 366 (85%) were caused by non-PCV7 serotypes and 67 (15%) were caused by PCV7 serotypes. 19A was the mo...Continue Reading

References

Jan 25, 2005·The Pediatric Infectious Disease Journal·Katherine HsuUNKNOWN Massachusetts Department of Public Health Epidemiologists
Feb 9, 2008·Emerging Infectious Diseases·Eun Hwa ChoiHoan Jong Lee
Nov 22, 2008·The Lancet Infectious Diseases·Ron Dagan, Keith P Klugman

❮ Previous
Next ❯

Citations

Aug 12, 2004·JAMA : the Journal of the American Medical Association·Gili Regev-YochayEthan Rubinstein
Jan 24, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Juan J CalixMoon H Nahm
Nov 9, 2010·The Pediatric Infectious Disease Journal·Anne J BlaschkeKrow Ampofo
Dec 31, 2010·Current Opinion in Pediatrics·Carlos G Grijalva, Stephen I Pelton
May 5, 2010·Antimicrobial Agents and Chemotherapy·Emilio Pérez-TralleroUNKNOWN Spanish Surveillance Group for Respiratory Pathogens
Apr 28, 2012·PloS One·Gili Regev-YochayUNKNOWN Palestinian-Israeli Collaborative Research Study Group
Dec 25, 2012·Emerging Infectious Diseases·Shamez N LadhaniElizabeth Miller
Oct 19, 2011·The Pediatric Infectious Disease Journal·Krow AmpofoCarrie L Byington
Mar 20, 2012·The Pediatric Infectious Disease Journal·Susanna EspositoUNKNOWN Italian Pneumococcal CAP Group
Dec 18, 2010·The Pediatric Infectious Disease Journal·Katherine K HsuUNKNOWN Members of the Massachusetts Department of Public Health
Dec 24, 2011·Future Microbiology·Neil D RitchieTom J Evans
Jun 19, 2012·Future Microbiology·Michael CunninghamItzhak Brook
Dec 18, 2010·Expert Review of Vaccines·E David G McIntosh, Ralf R Reinert
Mar 5, 2011·Indian Journal of Pediatrics·Sunil Karande
Apr 16, 2011·Lancet·Daniel M WeinbergerMarc Lipsitch
Aug 4, 2011·Expert Review of Vaccines·David S FedsonSandrine I Samson
Sep 16, 2011·Vaccine·Adriano ArguedasArturo Abdelnour
Jul 9, 2014·Pediatrics·Pui-Ying Iroh TamStephen I Pelton
Dec 14, 2011·The Journal of Infectious Diseases·Lee M HamptonMatthew Moore
Oct 17, 2012·Paediatric Respiratory Reviews·Sam Mehr, Nicholas Wood
Feb 15, 2012·Vaccine·Jae-Hoon SongBernard Fritzell
Mar 20, 2012·Médecine et maladies infectieuses·P Chavanet
Aug 7, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L F Pittet, K M Posfay-Barbe
Dec 1, 2012·Journal of the Pediatric Infectious Diseases Society·Derek J Williams, Samir S Shah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.